Morphogenesis and Veterinary Oncology ... - Morphogenesis, Inc.

Contact:

Pat Lawman, CEO-Morphogenesis, Inc. [email protected] 813-875-6600 extension 102

Morphogenesis and Veterinary Oncology Services to showcase multi-indication veterinary immunotherapies at the 2016 Veterinary Cancer Society Conference Tampa, FL (October 10, 2016) Morphogenesis, Inc. and its veterinary subsidiary, Veterinary Oncology Services, Inc. (VOS), will be making several presentations at the Veterinary Cancer Society’s (VCS) 36th Annual Conference at the Hilton Lake Buena Vista Resort in Orlando, FL, October 20-22, 2016. VOS will also be hosting a booth to promote its IFxVET personalized immunotherapy for pets with cancer. VCS expects nearly 1,000 registered attendees and approximately 80 exhibitors will be on hand. While VOS has made presentations at VCS conferences in the past, this is its first year as an exhibitor. “We are not only hoping to meet personally with the many veterinary oncologists that currently use our IFx-VET services, our goal is to also increase awareness of this non-toxic immunotherapy among the veterinary oncology community,” says VOS Director of Business Development, Mr. Steve Hazell. In addition to the exhibit promoting the personalized IFx-VET immunotherapy that is currently available to veterinarians across the U.S., there will be two poster presentations giving a high level summary of the results from the Company’s IFx-VETDirect, a direct injectable plasmid DNA, study in equine melanoma. One poster will summarize the clinical data derived from this 26-horse study, in which the vaccine is directly injected into the melanoma lesions. The second poster summarizes the cellular immune response to the therapy by simultaneously profiling cytokine production with the type of immune response elicited. “We are really stretching the boundaries of the current knowledge base of immunotherapy, multi-indication approaches, equine melanoma and analytical assays with this study” according to Dr. Patricia Lawman, Chief Executive Officer of Morphogenesis. “This is all pretty much uncharted territory that our team has been able to navigate.” “The results from this study are particularly exciting because the direct intratumoral injection of the plasmid DNA showed no toxic side effects and was clinically beneficial in treating horses with melanoma, a disease with no standard of care affecting millions of horses. There are many indications that the same therapy can be used to treat different types of cancer in dogs and cats in the near future,” says Kimberly Clark, VOS’ Chief Marketing Officer. “Obtaining a commercial license for this product will enable further studies and greatly extend the number of companion animals that can receive this safe and cost effective off-the-shelf immunotherapy.”

For more information, please follow us on LinkedIn, Facebook, Twitter and YouTube and visit/call; www.veterinaryoncologyservices.com, www.ifx-vet.com or 813-877-7896 www.morphogenesis-inc.com or 813-875-6600

4613 N Clark Avenue Tampa, FL 33614 Phone: 813 875 6600

Fax: 813 874 6500 www.morphogenesis-inc.com